The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

PDL BioPharma to Announce Third Quarter 2012 Financial Results on November 5, 2012

Thursday, November 01, 2012

PDL BioPharma to Announce Third Quarter 2012 Financial Results on November 5, 201216:00 EDT Thursday, November 01, 2012INCLINE VILLAGE, Nev., Nov. 1, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter financial results for the period ended September 30, 2012, on Monday, November 5, 2012, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results.  A slide presentation relating to the call will be available via the webcast link on the PDL website.(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Conference Call DetailsTo access the live conference call via phone, please dial (877) 303-9145 from the United States and Canada or (760) 536-5203 internationally. The conference ID is 55617262. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through November 12, 2012, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 55617262.To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.About PDL BioPharmaPDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new revenue generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com. NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc. SOURCE PDL BioPharma, Inc.For further information: Bruce Tomlinson, PDL BioPharma, Inc., +1-775-832-8500, bruce.tomlinson@pdl.com, or Jennifer Williams, Cook Williams Communications, +1-360-668-3701, jennifer@cwcomm.org